Treatment of Infective Endocarditis in Early Prosthetic Valve Patients or Healthcare-Associated Settings Before Pathogen Identification
When infective endocarditis occurs on a prosthetic valve within the first year after surgery, or arises in a nosocomial or non-nosocomial healthcare-associated context, the causative pathogen is frequently unknown at the time empirical treatment must begin. This clinical situation calls for a specific antibiotic strategy distinct from native-valve or late-onset disease.
Clinical Scenario
Early prosthetic valve infective endocarditis (valve surgery <12 months prior), or nosocomial / non-nosocomial healthcare-associated infective endocarditis — in both cases before the causative pathogen has been identified.
Empirical Treatment Approach
Current evidence supports a combination antibiotic regimen in this setting. The approach involves selecting between two specific intravenous agents as the backbone, then adding two further antimicrobials to broaden coverage.
References
In patients with early PVE (<12 months post-surgery) or nosocomial and non-nosocomial healthcare-associated IE, vancomycin or daptomycin combined with gentamicin and rifampin may be considered using the following doses:
DOI: 10.1093/eurheartj/ehad193
View source ↗